

1. Reporte	r Details			\Box Initial	□Follow-up
Reporter Name:			E-mail:		
Contact ad	dress:		Telephone nur	mber:	
			Fax number:		
Type:	Physician (Specialty):		Consumer or other non healthcare professional		
	Pharmacist		Other (Specify)		
If reporter i	s a consumer, have they inf	ormed their physician of the	ne exposure?	□ Yes	🗆 No
Has the consumer provided permission to contact their healthcard			e professional?	□ Yes	🗆 No
If yes, plea	se provide healthcare prof				
Name: Type:				Telephone:	
Address:				Email:	

2. Patient Details						
Date of birth (Day/Month/Year)	Age	Height cm	Weight kg			
	Yrs/mo.		e			

3.0	Company Drug Section								
	Name	Strength	Dose	Route	Indication	Treatment	Treatment	Lot	Expiry
						start date	end date		
						(day/month/year)	(day/month/year)		
1.									
2.									
3.									

4. Details of Adverse Event						
Adverse Event	Start Date	Stop Date	Outcome			
			Recovered / Resolved			
			Recovered / Resolved With Sequelae			
			□ Recovering /Resolving			
			□ Not Recovered /Not Resolved			
			🗆 Fatal			
			□ Unknown			

5. Medical History				
Medical History	 IBD History 			
(Enter all treatments below)	Specify Type			
	Date of Diagnosis			
	Therapies Received			
	 Malignancy 			
	Specify Type			
	Date of Diagnosis			
	 Immune Deficiency 			
	Human Immunodeficiency Virus (+/-)			
	If (+), Date of Diagnosis			

Mantra Pharma inc. | 9150 boul. Leduc, bur. 201, Brossard (Qc) J4Y 0E3

1-833-248-7326 | medinfo@mantrapharma.ca



	If (+), CD4 Count (at time of PML diagnosis)
	 Ongoing graft-versus-host disease (Yes/No)
Prior Treatments for IBD:	 Long-term immunosupression (ie. greater than 8 weeks) (Yes/No) Include medications, dose, route, frequency, start/stop dates for each medication/treatment received.
Prior Treatments for Other Important Past Medical History Condition	ons:

6. PML Disease

Signs and Symptoms of PML (include onset date(s) for each sign and symptoms)

Neurology Examinations (include date examination was conducted and results of examination)

Brain MRI / Brain Imaging Studies (include date of MRI and MRI results, types and results of other brain imaging studies)

Lumbar Puncture Results (document all lumbar punctures, especially date of lumbar puncture of the first JCV DNA (+) cerebrospinal fluid (CSF) result)

Brain Biopsy (include date of brain biopsy, highlights of brain biopsy pathology report, evidence of JCV on immunohistochemistry or FISH staining)

7. Labs					
	Date (day/month/year)	Results	Normal Range		
White Blood Cell Count	, , , , , , , , , , , , , , , , , , ,				
White Blood Cell Count Differential					
Hemoglobin					
Hematocrit					
Platelet Count					
Other					
JCV Antibody Status					

Confidentiel Mantra Pharma inc. | 9150 boul. Leduc, bur. 201, Brossard (Qc) J4Y 0E3 1-833-248-7326 | medinfo@mantrapharma.ca



JCV DNA (non-CSF sources		
for JCV testing)		

8. PML Diagnosis and Treatment					
Date of PML Diagnosis (day/month/year)	Plasma Exchange (PLEX) /	Other PML Treatments (include type of			
	Immunoadsorption (IA)	treatment(s), dose, route, frequency, start/stop dates			
	\Box PLEX	for each treatment received)			
Date of Permanent Discontinuation of					
Teriflunomide Treatment (day/month/year)	Dates of treatment:				
	Number of cycles:				

9. Follow-Up		
Any treatments for underlying disease post-PML diagnosis:	\Box Yes \Box No	
If yes, specify:		
PML Outcome:		
Event of PML continuing: \Box Yes \Box No		
Current clinical status of patient:		
Outcome of the event:		
□ Recovered / Resolved □ Recovered / Resolved With Sequelae	□ Recovering /Resolving	□ Not Recovered /Not Resolved
🗆 Fatal 🛛 Unknown		
If PML resulted in fatal outcome, provide date of death (day/mon	th/year):	
Cause of death:		
Autopsy conducted (and report available): \Box Yes \Box No		

10. Completed By					
Name:	Signature:	Date (day/month/year):			